Bradford P A, Petersen P J, Tuckman M, Jones C H
Infectious Diseases Discovery Research, Wyeth Research, Pearl River, NY 10965, USA.
Clin Microbiol Infect. 2008 Sep;14(9):882-6. doi: 10.1111/j.1469-0691.2008.02063.x.
The in vitro activity of tigecycline was evaluated against baseline pathogens isolated from patients enrolled in phase 3 clinical trials for community-acquired pneumonia conducted in 29 countries worldwide. Tigecycline was active against the most prevalent pathogens, including Streptococcus pneumoniae (MIC(90) 0.06 mg/L), Staphylococcus aureus (MIC(90) 0.25 mg/L), Haemophilus influenzae (MIC(90) 0.5 mg/L) and Klebsiella pneumoniae (MIC(90) 1 mg/L). Twelve isolates of S. pneumoniae expressing tet(M) and two isolates of K. pneumoniae producing extended-spectrum beta-lactamases isolated during the study were susceptible to tigecycline. The excellent in vitro activity of tigecycline against these clinical isolates confirmed its potential utility against pathogens associated with community-acquired pneumonia.
对替加环素的体外活性进行了评估，受试对象为从全球29个国家开展的社区获得性肺炎3期临床试验入组患者中分离出的基线病原体。替加环素对最常见的病原体具有活性，包括肺炎链球菌（MIC90为0.06mg/L）、金黄色葡萄球菌（MIC90为0.25mg/L）、流感嗜血杆菌（MIC90为0.5mg/L）和肺炎克雷伯菌（MIC90为1mg/L）。研究期间分离出的12株表达tet(M)的肺炎链球菌菌株以及2株产超广谱β-内酰胺酶的肺炎克雷伯菌菌株对替加环素敏感。替加环素对这些临床分离株具有出色的体外活性，证实了其对社区获得性肺炎相关病原体的潜在效用。
